Showing results (31-40 of 552) with videos related to
Sort By:
Pageof 56
Cell Growth & Differentiation : the Molecular Biology Journal of the American Association for Cancer Research|June 1, 1995
Phorbol ester stimulated cathepsin L expression in U937 cellsK B Atkins, B R TroenExpert Opinion on Investigational Drugs|August 7, 2010
Molecular targeted therapy for patients with melanoma: the promise of MAPK pathway inhibition and beyondRyan J Sullivan, Michael B AtkinsAmerican Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|May 27, 2014
New agents and new targets for renal cell carcinomaGeorge K Philips, Michael B AtkinsCancer Medicine|January 10, 2014
PD-1 as a potential target in cancer therapyDavid F McDermott, Michael B AtkinsMethods in Molecular Biology (Clifton, N.J.)|November 22, 2013
Emerging clinical issues in melanoma in the molecularly targeted eraRyan J Sullivan, Michael B AtkinsJournal for Immunotherapy of Cancer|August 27, 2025
How can we increase the value of clinical trials with immunotherapy?Michael B Atkins, David F McdermottExpert Opinion on Emerging Drugs|August 20, 2016
Emerging monoclonal antibodies for the treatment of renal cell carcinoma (RCC)Michael B Atkins, George K PhilipsCurrent Urology Reports|December 22, 2004
Chemotherapies and immunotherapies for metastatic kidney cancerYoo-Joung Ko, Michael B AtkinsClinical Advances in Hematology & Oncology : H&O|September 10, 2015
Immunotherapy or molecularly targeted therapy: what is the best initial treatment for stage IV BRAF-mutant melanoma?Geoffrey T Gibney, Michael B AtkinsBlood|October 1, 1995
Comparative responsiveness of HL-60, HL-60R, and HL-60R+ (LRARSN) cells to retinoic acid, calcitriol, 9 cis-retinoic acid, and sodium butyrateK B Atkins, B R TroenPageof 56